1.37
전일 마감가:
$1.40
열려 있는:
$1.38
하루 거래량:
2.08M
Relative Volume:
0.66
시가총액:
$1.09B
수익:
$711.41M
순이익/손실:
$-133.73M
주가수익비율:
-7.2105
EPS:
-0.19
순현금흐름:
$-199.99M
1주 성능:
+1.48%
1개월 성능:
+7.87%
6개월 성능:
-7.43%
1년 성능:
-3.52%
Opko Health Inc Stock (OPK) Company Profile
명칭
Opko Health Inc
전화
305-575-4181
주소
4400 BISCAYNE BLVD., MIAMI, FL
OPK을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
OPK
Opko Health Inc
|
1.37 | 1.11B | 711.41M | -133.73M | -199.99M | -0.19 |
![]()
TMO
Thermo Fisher Scientific Inc
|
478.32 | 179.32B | 43.21B | 6.58B | 6.17B | 17.29 |
![]()
DHR
Danaher Corp
|
205.48 | 145.22B | 24.01B | 3.41B | 4.86B | 4.70 |
![]()
IDXX
Idexx Laboratories Inc
|
565.19 | 44.23B | 3.93B | 894.97M | 837.70M | 10.82 |
![]()
IQV
Iqvia Holdings Inc
|
199.17 | 34.14B | 15.50B | 1.33B | 2.16B | 7.34 |
![]()
A
Agilent Technologies Inc
|
120.18 | 34.19B | 6.63B | 1.17B | 1.19B | 4.05 |
Opko Health Inc Stock (OPK) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2025-04-25 | 개시 | JP Morgan | Neutral |
2023-06-29 | 업그레이드 | Barrington Research | Mkt Perform → Outperform |
2022-12-15 | 개시 | H.C. Wainwright | Buy |
2022-01-24 | 다운그레이드 | Barrington Research | Outperform → Mkt Perform |
2021-06-21 | 개시 | Ladenburg Thalmann | Buy |
2019-11-25 | 개시 | Piper Jaffray | Overweight |
2018-03-02 | 다운그레이드 | JP Morgan | Neutral → Underweight |
2017-09-14 | 다운그레이드 | JP Morgan | Overweight → Neutral |
2016-06-21 | 재확인 | Standpoint Research | Buy |
2016-06-03 | 개시 | Standpoint Research | Buy |
2016-03-31 | 재확인 | Barrington Research | Outperform |
2015-10-16 | 개시 | JP Morgan | Overweight |
2015-09-11 | 다운그레이드 | Jefferies | Buy → Hold |
2015-03-03 | 다운그레이드 | Oppenheimer | Outperform → Perform |
2014-05-12 | 재확인 | Oppenheimer | Outperform |
2014-03-14 | 개시 | Oppenheimer | Outperform |
2013-11-13 | 재확인 | Ladenburg Thalmann | Buy |
2013-05-30 | 재확인 | Ladenburg Thalmann | Buy |
2012-10-22 | 개시 | Barrington Research | Outperform |
2011-12-01 | 재확인 | Ladenburg Thalmann | Buy |
2011-07-14 | 개시 | Ladenburg Thalmann | Buy |
모두보기
Opko Health Inc 주식(OPK)의 최신 뉴스
What drives OPKO Health Inc. stock priceExplosive capital appreciation - PrintWeekIndia
Is OPKO Health Inc. stock a good hedge against inflationDynamic capital growth - jammulinksnews.com
OPKO Health to Report Second Quarter 2025 Financial Results on July 31 - OPKO Health, Inc.
Investors in OPKO Health (NASDAQ:OPK) From Five Years Ago Are Still Down 75%, Even After 5.1% Gain This Past Week - 富途牛牛
The recent 5.1% gain must have brightened CEO Phillip Frost's week, OPKO Health, Inc.'s (NASDAQ:OPK) most bullish insider - simplywall.st
What analysts say about OPKO Health Inc. stockTurbocharged investment results - Autocar Professional
OPKO Health’s (OPK) Oral GLP-2 Analog Selected for a Poster Presentation in Collaboration with Entera Bio (ENTX) - Insider Monkey
Is OPKO Health Inc. a good long term investmentSkyrocketing returns - jammulinksnews.com
OPKO Health Inc. Stock Analysis and ForecastTremendous portfolio expansion - jammulinksnews.com
11 Best American Penny Stocks to Buy According to Analysts - Insider Monkey
Quote - OPKO Health, Inc.
How high can OPKO Health Inc. stock price go in 2025Predictable Return Stock Picks - beatles.ru
Is now a good time buy $OPK - AInvest
OPKO Health (NASDAQ:OPK) Stock Rating Upgraded by LADENBURG THALM/SH SH - MarketBeat
OPKO Health, Inc. (NASDAQ:OPK) Receives $2.75 Consensus Price Target from Analysts - MarketBeat
H.C. Wainwright Reiterates a Buy Rating on Opko Health (OPK), Keeps the PT at $3 - MSN
Opko Health (OPK) Has a New Rating from Ladenburg Thalmann & Co. - The Globe and Mail
Capital Advisors Inc. OK Increases Holdings in OPKO Health, Inc. (NASDAQ:OPK) - MarketBeat
OPKO Health and Entera Bio Announce Abstract on PK/PD of - GlobeNewswire
OPKO Health and Entera Bio abstract selected for ESPEN Congress - StreetInsider
OPKO Health and Entera Bio Announce Abstract on PK/PD of Oral GLP-2 Tablet for the Treatment of Short Bowel Syndrome Selected for 2025 ESPEN Congress - Yahoo Finance
Breakthrough: First-Ever Oral Tablet Could Replace Daily Injections for Short Bowel Syndrome Treatment - Stock Titan
13 Stocks Under $5 With High Upside Potential - Insider Monkey
Investor Network: OPKO Health, Inc. to Host Earnings Call - ACCESS Newswire
OPKO Health (OPK) to Present OPK-88006 Data at ENDO 2025 - MSN
OPKO Health's Russell 2000 Defensive Index Inclusion: A Catalyst for Strategic Revaluation - AInvest
The Next Wave in Obesity Treatment: OPKO's OPK-88006 and Its Dual-Format Strategy - AInvest
Opko Health Inc (OPK) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Opko Health Inc 주식 (OPK) 내부자 거래
내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
---|---|---|---|---|---|---|---|
FROST PHILLIP MD ET AL | CEO & Chairman |
Apr 08 '25 |
Buy |
1.48 |
125,000 |
184,650 |
213,876,448 |
FROST PHILLIP MD ET AL | CEO & Chairman |
Apr 01 '25 |
Buy |
1.65 |
100,000 |
164,850 |
213,751,448 |
FROST PHILLIP MD ET AL | CEO & Chairman |
Mar 28 '25 |
Buy |
1.70 |
150,000 |
254,385 |
213,651,448 |
FROST PHILLIP MD ET AL | CEO & Chairman |
Mar 17 '25 |
Buy |
1.74 |
200,000 |
347,820 |
213,501,448 |
FROST PHILLIP MD ET AL | CEO & Chairman |
Feb 28 '25 |
Buy |
1.71 |
67,434 |
115,312 |
213,301,448 |
FROST PHILLIP MD ET AL | CEO & Chairman |
Jan 28 '25 |
Buy |
1.47 |
47,537 |
70,060 |
213,234,014 |
FROST PHILLIP MD ET AL | CEO & Chairman |
Jan 17 '25 |
Buy |
1.47 |
150,000 |
220,425 |
213,186,477 |
FROST PHILLIP MD ET AL | CEO & Chairman |
Jan 15 '25 |
Buy |
1.48 |
500,000 |
740,850 |
213,036,477 |
FROST PHILLIP MD ET AL | CEO & Chairman |
Dec 13 '24 |
Buy |
1.59 |
125,000 |
199,375 |
212,536,477 |
FROST PHILLIP MD ET AL | CEO & Chairman |
Dec 11 '24 |
Buy |
1.56 |
500,000 |
781,050 |
212,411,477 |
자본화:
|
볼륨(24시간):